Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 2 | Poster Presentation | The Multi-physics Automated Reconfigurable Separation (MARS®) System Provides High Purity, High Recovery and High Throughput Enrichment of Immune Cells for Immunotherapy | Liping Yu, MD Ph.D.; Gregory Schneider, Ph.D.; Alice Wang, Ph.D.; | Biomarkers, Immune Monitoring and Novel Technologies | CAR T cells; Immune monitoring; Inflammation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 3 | Poster Presentation | Butyrophilin-3A is Expressed in Multiple Solid Tumors: Translational Research Supporting the EVICTION Study with ICT01, an Anti-BTN3A mAb activating Vg9Vd2 T-Cells | Clement Ghigo; Aude de Gassard; Patrick Brune; Caroline Imbert; Clemence Demerle; Marie-Sarah Rouviere; René Hoet; Daniel Olive; Emmanuel Valentin, PhD; Emmanuel Valentin, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Biomarkers; Immune monitoring; T cell; Targeted therapy |
| 4 | Poster Presentation | Molecularly guided multiplexed digital spatial analysis reveals differential gene expression profiles in the WNT-β-catenin pathway between melanoma and prostate tumors | Anushka Dikshit, PhD; Dan Zollinger; Karen Nguyen; Jill McKay-Fleisch; Kit Fuhrman, MS PhD; Xiao-jun Ma, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; RNA; Solid tumors; Tumor microenvironment |
| 5 | Poster Presentation | Multiple Myeloma Flow Cytometry Panel Validated for Clinical Monitoring of Patients | Bevan Gang, PhD; Vicky Sgouroudis, PhD; Virginia Litwin; Anita Boyapati; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; B cell; Biomarkers; Immune monitoring; Tumor antigens |
| 6 | Poster Presentation | Pre-clinical pharmacodynamic biomarker assays of immune modulation can translate to inform exploratory endpoints of target engagement in first-in-human clinical trial stages of drug discovery | Russell J. Garland, PhD; Christopher Kirkham, PhD; Michelle Yap, PhD; Louise S. Brackenbury, PhD; Tommaso Iannitti, PhD; Robert Nunan; S R. Jenkinson; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Inflammation; T cell; T cell lineages |
| 7 | Poster Presentation | Prognostic Factors for Overall Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Therapy – The MELimmune Score | Soraia Lobo-Martins, MD; Diogo Martins-Branco; Patrícia Miguel Semedo; Cecília Melo Alvim; Ana Maria Monteiro; Inês Vendrell; Emanuel Gouveia; Maria José Passos; Luís Costa; André Mansinho; Rita Teixeira de Sousa; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Inflammation; Solid tumors |
| 8 | Poster Presentation | Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist | Aung Naing, MD, FACP; Daniel D. Karp, MD; Sarina A. Piha-Paul, MD; Cara Haymaker, PhD; Edwin R. Parra, MD, PhD; Fei Yang, MD, Ph.D.; Shubham Pant, MD; David S. Hong, MD; Siqing Fu, MD, PhD; Timothy A. Yap, MD, PhD; Bettzy Stephen, MBBS; Yali Yang, PhD; Heather Lin, MS, PhD; Cheuk Hong Leung, MS; Naval Daver, MD; Yeonjoo Choi, MD; Joud Hajjar, MD; Ignacio Wistuba, MD; Patrick M. Hwu, MD; Funda Meric-Bernstam, MD; Jordi Rodon; | Biomarkers, Immune Monitoring and Novel Technologies | Antigen presenting cells; Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors |
| 9 | Poster Presentation | Mesenchymal Features of a Novel 27-Gene Algorithm Associate with Canonical Tumor Promoting Signaling Pathways which may Identify Therapeutic Options for Immunotherapy Resistant Patients | Tyler J. Nielsen, MS; Rob S. Seitz; Douglas T. Ross, MD, PhD; David R. Hout, PhD; Brock L. Schweitzer, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Angiogenesis; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 10 | Poster Presentation | A multiparameter flow cytometry assay to monitor natural killer cell proliferation and activation in immuno-oncology clinical trials | Jennifer Tsau, PhD; Brittney Atzmiller; David Quinn, PhD; Tanya Mulvey; Sema Kurtulus, PhD; Jennifer Mataraza, PhD; Shabnam Tangri, PhD; Naveen Dakappagari, PhD; Ghanashyam Sarikonda, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical trial; Monocyte/Macrophage; NK/NK T cell; T cell |
| 11 | Poster Presentation | A Multi-physics Approach Enabling Rare Cell Isolation with High Recovery and High Purity | Liping Yu; Silin Sa, PhD; Alice Wang, Ph.D.; | Biomarkers, Immune Monitoring and Novel Technologies | B cell; Biomarkers; Gene expression; NK/NK T cell; Proteomics; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 12 | Poster Presentation | Development of an in vitro assay to assess bispecific T cell engager using T cells from CD3e humanized mice | Jun Zhou; Shuang Zhu; Hongjuan Zhang, PhD; Lei Zheng; Mingfa Zang; Annie Xiaoyu An; Shuzong Wang; Davy Xuesong Ouyang; Henry Q. Li; Yujun Huang; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Bispecifics; T cell |
| 13 | Poster Presentation | Use of anti-viral T cells to model HLA-restricted anti-tumor cytotoxic lymphocyte responses | Michael Overstreet, PhD; Vanessa M. Muniz-Medina; Ruoyan Chen; James Kurasawa; Stacy R. Kentner; Deepali Malhotra, PhD; Jane Osbourn; Jill Walker; Gordon Moody; Michael Overstreet, PhD; Michael Overstreet, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Adoptive immunotherapy; Checkpoint blockade; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 14 | Poster Presentation | Novel CD3 epsilon humanized N-terminal epitope model for assessment of efficacy of T-cell engagers | Gaëlle Martin; Fabiane Sonego; Audrey Beringer; Chloé Beuraud; Yacine Cherifi; Alexandre Fraichard; Patricia Isnard-Petit; Kader Thiam, PhD; Fabiane Sônego, PhD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bispecifics; Inflammation; T cell; Targeted therapy |
| 15 | Poster Presentation | A novel CD28 humanized mouse model for efficacy assessment of CD28-targeting therapies | Fabiane Sônego, PhD, MS; Gaelle Martin, PhD; Chloé Beuraud; Audrey Beringer; Yacine Cherifi; Alexandre Fraichard; Patricia Isnard-Petit; Kader Thiam; | Biomarkers, Immune Monitoring and Novel Technologies | Costimulation; Inflammation; T cell; Targeted therapy |
| 16 | Poster Presentation | Antibody profiling of prostate cancer patients reveals differences in antibody signatures among disease stages and following treatment | Hemanth K. Potluri, BA; Hemanth K. Potluri, BA; Tun Lee Ng; Michael A. Newton, PhD; Jin Zhang, PhD; Christopher A. Maher, PhD; Peter S. Nelson, MD; Douglas G. McNeel, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Autoimmunity; Bioinformatics; Biomarkers; Vaccine |
| 17 | Poster Presentation | Activity sensors for noninvasive monitoring of immune response and tumor resistance during immune checkpoint blockade therapy | Quoc Mac, BS; James Bowen; Hathaichanok Phuengkham; Anirudh Sivakumar; Congmin Xu; Fang-Yi Su; Samuel Z. Stentz; Hyoung Sim; Adrian Harris; Tonia Li; Peng Qiu; Gabriel Kwong; Quoc Mac, BS; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 18 | Poster Presentation | New method of assessing tumor heterogeneity utilizing both circulating tumor DNA and tissue DNA to predict the response to immunotherapy | Jaeyoun Choi, M.D.; Myungwoo Nam, MD; Stanislav Fridland; Jinyoung Hwang; Chan Mi Jung; Christmann Low; Young Kwang Chae, MD, MPH, MBA; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade |
| 19 | Poster Presentation | Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients | Zheng Feng; Juergen Scheuenpflug, PhD; Mengyao Tan; Danyi Wang; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Neoantigens; Regulatory T cell (Treg cell); RNA; Solid tumors; T cell; Tumor microenvironment |
| 20 | Poster Presentation | Quantification of sBCMA in Human Plasma using a High-Throughput Mass Spectrometry Workflow for Exploratory, CAP/CLIA or Regulated Studies | Luca Genovesi, PhD; Michael Schirm; Gwenaël Pottiez; Rudolf Guilbaud; Lorella Di Donato; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical trial; Leukemia/Lymphoma; Proteomics |
| 21 | Oral Presentation | Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients | Michal Harel, PhD; Coren Lahav, MSc; Eyal Jacob, PhD; Eran Issler, MSc; Haim Bar, PhD; Adam P. Dicker, MD, PhD; Ofer Sharon, MD; Antonietta Bacchiocchi, MSc; Ruth Halaban, PhD; Mario Sznol, MD; Yuval Shaked, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Checkpoint blockade; Clinical trial; Immune suppression; Proteomics; Solid tumors; Systems biology |
| 23 | Poster Presentation | Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA4 rescue in patients with mismatch repair deficient metastatic colorectal cancer | Pashtoon M. Kasi, MD, MS; Carlos HF. Chan, MD, PhD; Pashtoon M. Kasi, MD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Neoantigens; Solid tumors; Tumor antigens; Tumor evasion |
| 24 | Poster Presentation | Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade | Pashtoon M. Kasi, MD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Neoantigens; Solid tumors |
| 25 | Poster Presentation | Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring | Georges Azzi, MD; Shifra Krinshpun, MS, LCGC; Antony Tin, PhD; Allyson K. Malashevich, PhD; Meenakshi Malhotra; Paul Billings, MD, PhD; Angel Rodriguez, MD; Alexey Aleshin, MD, MBA; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Immune adjuvant |
| 26 | Poster Presentation | ctDNA clearance and radiographic resolution of lymph node metastasis in a patient with metastatic microsatellite stable colorectal cancer on immunotherapy | Charles J. Schneider, MD, FACP; Michael Krainock, MD; Meenakshi Malhotra; Paul Billings, MD, PhD; Alexey Aleshin, MD, MBA; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Chemotherapy; Immune adjuvant; Solid tumors |
| 27 | Poster Presentation | The role of ligands of activatory receptor NKG2D in the immune-dependent pathogenesis and evolution of inflammatory bowel disease (IBD) | Heba Sidahmed; Shilpa Ravindran, MSc; Harshitha S. Manjunath; William Mifsud; Adrian Charles; Adham A. Ammar; Muhammad U. Khan; Saad Al-Kaabi; Anthony Akobeng; Muneera J. Al-Mohannadi; Mamoun Elawad; Sara Tomei, PhD; Cristina Maccalli, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Autoimmunity; Biomarkers; Gene expression; Genetic polymorphism; Inflammation |
| 28 | Poster Presentation | Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies | Michael Smith, PhD; Robert C. Newton; Sherry Owens; Xiaohua Gong, PhD; Chuan Tian, PhD; Janet Maleski, RN, BSN; Lance Leopold, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Coinhibition; Inflammation; Tumor microenvironment |
| 29 | Poster Presentation | Profiling Tumor Circulating Cell-Free DNA with an Enhanced Whole-Exome to Enable Sensitive Assessment of Somatic Mutations | Simo V. Zhang, PhD; Mengyao Tan; Fabio C. P. Navarro; Josette M. Northcott; Shuyuan Ma; Christopher S. Nelson; Devayani P. Bhave, PhD; L. Gordon Bentley; Manju Chinnappa; Dan Norton; Gabor Bartha, PhD; Jason Harris; John Lyle, PhD; Sean M. Boyle, PhD, MS; John S. West, MBA; Richard Chen, MD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Immune monitoring |
| 34 | Poster Presentation | Multi-step antibody validation for the GeoMx® Digital Spatial Profiler | Alyssa Rosenbloom; Jenny Cronin; Shilah A. Bonnett, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Biomarkers; Immune monitoring; Proteomics |
| 37 | Poster Presentation | Monitoring the evolution of inflammatory bowel disease (IBD) in pediatric and adult cohorts of patients to identify biomarkers to predict cancer risk | Shilpa Ravindran, MSc; Heba Sidahmed; Harshitha S. Manjunath; Rebecca A. Mathew, MSc; Tanwir Habib; William Mifsud; Adrian Charles; Adham A. Ammar; Muhammad U. Khan; Saad Al-Kaabi; Anthony Akobeng; Muneera J. Al-Mohannadi; Mamoun Elawad; Sara Tomei, PhD; Cristina Maccalli, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Autoimmunity; Biomarkers; Epigenetics; Gene expression; Inflammation; RNA; Stem cell/cancer-initiating cell |
| 38 | Poster Presentation | Clinical validation of an image analysis assay for determining programmed death-ligand 1 (22C3) in non-small cell lung cancer | Roberto Gianani, MD, FCAP; Will Paces, MEng; Elliott Ergon, BS; Kristin Shotts, PhD; Vitria Adisetiyo, PhD; Vitria Adisetiyo, PhD; Charles Caldwell, Jr., PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Biomarkers; Clinical study; Solid tumors |
| 39 | Poster Presentation | Spatial single-cell quantitative analyses of human head and neck squamous cell carcinomas | Katie E. Blise, BA; Shamilene Sivagnanam, MS; Lisa M. Coussens, PhD; Jeremy Goecks, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Immune contexture; Solid tumors; Systems biology; Tumor microenvironment |
| 40 | Poster Presentation | The Orion™ platform from RareCyte® enables same-day 21-plex fluorescence tissue analysis | Daniel Campton; Jeremy Cooper; Steven Reese; Kyla Teplitz; Jeffrey Werbin; Joshua Nordberg; Eric P. Kaldjian, MD; Tad George, PhD | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 41 | Poster Presentation | Optimization of an ultrasensitive, quantitative immunoassay for detection of CD20 in Non-Hodgkin's Lymphoma (NHL) FFPE samples | Apollina Goel, PhD; Michael Ross; Jeanette Rheinhardt; Peter Duval; Michael Maker; Hiroyuki Yokota; Kenneth Bloom; George Abe; Ann Ranger; Joseph S. Krueger, BS PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; B cell; Biomarkers; Bispecifics; Leukemia/Lymphoma; Tumor antigens |
| 42 | Poster Presentation | Intravital multiphoton microscopy of infiltrating T cell and tumor cell metabolism in a murine melanoma model | Alexa R. Heaton, PhD; Tiffany M. Heaster, PhD; Anna Hoefges, MS; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Adoptive immunotherapy; Checkpoint blockade; Cytokine; Metabolism; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 43 | Poster Presentation | Highly multiplexed digital spatial profiling of the tumor microenvironment of non-small-cell lung cancer (NSCLC) | Arutha J. Kulasinghe, PhD; Connor O'Leary; Rahul Ladwa; Majid Warkiani, PhD; Kenneth J. O'byrne, MD; Arutha J. Kulasinghe, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 46 | Poster Presentation | A novel H&E-like staining method compatible with multiplexed IF on the same tissue section for integrated translational workflows | Michael J. McLane, II; Glenn Milton; Linying Liu; Rachel Schaefer; Yi Zheng; Carla Coltharp, PhD; Peter Miller, MS; Clifford C. Hoyt, MS; Michael J. McLane, II, BS; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Immune contexture; Tumor microenvironment; Tumor stroma |
| 47 | Poster Presentation | Pathologists enhance interpretation of automated multiplex immunohistochemistry assays in cancer immunotherapy trials | Emmanuel Pacia; Ju Young Kim, PhD; Evelyn Diaz; Beiru Chen, MD; Nathan Roscoe; Jason Hughes; Thai Tran, PhD; Jennifer M. Bordeaux, PhD; Bashar Dabbas, MD; Shabnam Tangri, PhD; Margaret McLaughlin, MD; Alexander Savchenko, MD, PhD; Naveen Dakappagari, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical study |
| 48 | Poster Presentation | Advances in Multiplexed Ion Beam Imaging (MIBI) for immune profiling of the tumor microenvironment | Jason Ptacek, PhD; Felipe C. Geyer, MD; Andre Mignault; James Deeds; Jimmy Giedt, Ph.D.; Jane Gu; Margaret McLaughlin, MD; Yari Sigal, Ph.D.; Jay G. Tarolli, Ph.D.; Murat Aksoy, Ph.D.; Yi Zhang; Monirath Hav, MD; Rachel Finck; Jessica Finn, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Dendritic cell; Immune contexture; Immune monitoring; Immune suppression; Solid tumors; Systems biology; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 49 | Poster Presentation | In situ phenotypic analysis of T cells in the tumor microenvironment of a pre-clinical model of non-small cell lung cancer (NSCLC) by tissue sectioning and whole-mount immunofluorescence imaging | Elen Torres, PhD; Stefani Spranger, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 50 | Poster Presentation | Spatially Resolved Molecular Investigation of Triple Negative Breast Cancer and Its Immune Microenvironment | Stephen R. Williams, PhD; Cedric R. Uytingco, PhD; Neil Weisenfeld, PhD; Nigel Delaney, PhD; Solongo Ziraldo, PhD; Yifeng Yin, PhD; Jennifer Chew, BS; Sharmila Chatterjee; Daniel P. Riordan, PhD; Zachary W. Bent, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | B cell; Bioinformatics; Biomarkers; Gene expression; Genetic polymorphism; RNA; Stem cell/cancer-initiating cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 52 | Poster Presentation | Advanced T Lymphocyte Analysis System (ATLAS) for In-depth Immunological Interrogation in Real-World Conditions, a Methodological Strategy | Stephanie Berg, DO; Stephanie Berg, DO; Cara Joyce, PhD; Michael Delos Reyes; Brianna Burke; Lourdes Plaza-Rojas, PhD; Kushal Prajapati; Cynthia Perez; Courtney Wagner, MD; Elizabeth Elliott, DO; Blaine Knox, MD; Daniel Linden, DO; Joseph I. Clark, MD; Jose Guevara, MD PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; T cell |
| 54 | Poster Presentation | Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues | Maxim Isabelle, PhD; Maxim Isabelle, PhD; Maxim Isabelle, PhD; Michael Schirm; Gwenaël Pottiez; Rudolf Guilbaud; Lorella Di Donato; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical study; Proteomics |
| 55 | Poster Presentation | Thousands of antigens are recognized in mice via endogenous antibodies after being cured of a B78 melanoma via immunotherapy | Anna Hoefges, MS; Amy K. Erbe, PhD; Sean J. Mcilwain, PhD; Trang Q. Le; Angie Xu; Nicholas Mathers; Eric Zhang; Andrew S. Melby; Claire Baniel; Alexander L. Rakhmilevich, MD, PhD; Jacquelyn A. Hank, PhD; Richard Pinapati, PhD; Brad Garcia, PhD; Jigar Patel, PhD; Zachary S. Morris, MD, PhD; Irene M. Ong, PhD; Paul M. Sondel, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Antigen presenting cells; B cell; Bioinformatics; Biomarkers; Neoantigens; Proteomics; Radiotherapy; Solid tumors; Tumor antigens |
| 56 | Poster Presentation | Improved next generation sequencing based Class I HLA typing through exome enhancement | Lee D. McDaniel, Jr., MD, MSE; Rachel M. Pyke, PhD; Charles Abbott, PhD; Gabor Bartha, PhD; John S. West, MBA; Richard Chen, MD, MS; Sean M. Boyle, PhD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Neoantigens |
| 57 | Poster Presentation | Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets | Dattatreya M. Mellacheruvu, PhD; Rachel M. Pyke, PhD; Charles Abbott, PhD; Nick Phillips, MS; Sejal Desai, PhD; Rena McClory, PhD; John S. West, MBA; Richard Chen, MD, MS; Sean M. Boyle, PhD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Neoantigens; Proteomics; Tumor antigens; Vaccine |
| 58 | Poster Presentation | Excluding Treg epitopes and integrating CD8 and CD4 effector neoepitope content improves prognostic biomarker tool in bladder cancer | Guilhem Richard, PhD; Gary D. Steinberg; Tzintzuni Garcia; Matthew Ardito, BA; William Martin, BA MD; Gad Berdugo, MBA, MSc.; Michael F. Princiotta, PhD; Arjun V. Balar, MD; Anne S. de Groot, MD; Randy F. Sweis, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Neoantigens; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor antigens; Vaccine |
| 59 | Poster Presentation | Integrating deep proteomics profiling with survival analysis to identify novel biomarkers of response to PD-1 blockade in NSCLC patients | Kamil Sklodowski, PhD; Vito Dozio, PhD; Silvia Lopez-Lastra, PhD; Andrés Lanzós, PhD; Kristina Beeler, Dr.; Emanuela Romano, MD, PhD; Kamil Sklodowski, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; Targeted therapy |
| 60 | Poster Presentation | Development and validation of blood tumor mutational burden reference standards | Eun-Ang Rabier-Moreau, PhD; Guillem Portella, PhD; Matthew Butler, PhD; Yves Konigshofer, PhD; James Hadfield, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers |
| 61 | Poster Presentation | Tumor mutational burden assessments by two commercial targeted sequencing assays | Ruchi Chaudhary; Gitanjali Vaidya; Meeta Sunil; Sakthivel Murugan S.M; Ramprasad VL; Ravi Gupta; Eric Stawiski; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade |
| 62 | Oral Presentation | Identify immune cell types and biomarkers associated with immune-related adverse events using single cell RNA sequencing | Jiamin Chen, PhD; Lance Pflieger, PhD; Sue M. Grimes, MSc; Tyler Baker, PhD; Michael Brems; Gail Fulde; Shawnee Snow; Parker Howe; Anuja Sathe, PhD; Bryce Christensen; Hanlee P. Ji, MD; Terence Rhodes, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Gene expression; Immune toxicity; Inflammation; T cell |
| 64 | Poster Presentation | Cancer testis antigen co-expression landscape in solid tumors | R.J. J. Seager, Jr., Ph.D.; Erik Van Roey; Shuang Gao; Jonathan Andreas, MS; Vincent Giamo, BS, MS; Blake Burgher, BS, RN; Felicia L. Lenzo; Mary K. Nesline, MS; Paul DePietro, PhD; Yirong Wang, M.S.; Sean T. Glenn, PhD; Shengle Zhang, MD; Jeffrey Conroy, BS; Sarabjot Pabla, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Solid tumors; Tumor antigens |
| 65 | Poster Presentation | PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer. | Yong Hee Lee; Grace K. Dy; Paul DePietro, PhD; Jeffrey Conroy, BS; Sarabjot Pabla, PhD; Mary K. Nesline, MS | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Chemotherapy; Gene expression; RNA; Solid tumors; Tumor microenvironment |
| 66 | Poster Presentation | Complex markers of survival from pembrolizumab: The potential predictive role of tumor mutational burden (TMB) and KRAS | Yong Hee Lee; Carrie Hoefer; Paul DePietro, PhD; Mary K. Nesline, MS | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; Solid tumors; Tumor microenvironment |
| 67 | Poster Presentation | B-cell receptor heavy chain repertoire profiling using an augmented transcriptome | Eric Levy, PhD; Pamela Milani, PhD; Gabor Bartha, PhD; Charles Abbott, PhD; Robert Power, MS; Rena McClory, PhD; Robin Li, MS; John S. West, MBA; John Lyle, PhD; Sean M. Boyle, PhD, MS; Richard Chen, MD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; B cell; Bioinformatics; Biomarkers; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 69 | Poster Presentation | Automated TRB locus haplotype analysis by long-amplicon TCRB chain sequencing for potential immune-related adverse events biomarker research | Jennifer Burke; Frances Chen; Jiajie Huang; Geoffrey M. Lowman, PhD; Timothy Looney, PhD; Marina Sedova, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Immune monitoring; Immune toxicity; T cell |
| 70 | Poster Presentation | Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro | Simarjot Pabla, PhD; Tenzing Khendu; Simarjot Pabla, PhD; Dhan Chand, PhD; Bulent A. Aksoy, PhD; Benjamin Duckless, BS; Andrew Basinski; Cailin CJ. Joyce, PhD; Thomas Horn, PhD; Lukasz Swiech; Jeremy D. Waight, PhD; David Savitsky, PhD; Jennifer S. Buell, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; T cell; Tumor evasion; Tumor microenvironment |
| 71 | Poster Presentation | Whole Exome Sequencing of individuals presenting extreme phenotypes of high and low-risk of developing tobacco-induced lung adenocarcinoma: relevance of immune and DNA-repair related pathways | Jose Perez-Gracia, MD; Mapi Andueza; Ana Patiño-Garcia, PhD; Alfonso Gurpide; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Carcinogenesis; Epidemiology; Genetic polymorphism; Solid tumors |
| 72 | Poster Presentation | Routine use of comprehensive genomic profiling to assess tumor mutational burden across a community health system | Carlo B. Bifulco, MD; Roshanthi Weerasinghe; Bela Bapat; Alexa K. Dowdell; Shwetha Pindikuri; Sheila Reynolds; Nancy Biery; David Ball; Mary Campbell; Thomas R. Ward; Alisha Stein; Brock E. Schroeder; David A. Eberhard, MD PhD; Brian D. Piening; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors |
| 73 | Poster Presentation | Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity | Rachel M. Pyke, PhD; Dattatreya M. Mellacheruvu, PhD; Charles Abbott, PhD; Eric Levy, PhD; Simo V. Zhang, PhD; Devayani P. Bhave, PhD; Manjula Chinnappa, PhD; Gabor Bartha, PhD; John Lyle, PhD; John S. West, MBA; Richard Chen, MD, MS; Sean M. Boyle, PhD, MS; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Neoantigens; Tumor antigens; Tumor evasion; Vaccine |
| 74 | Poster Presentation | Novel approach for profiling immune-tumor cell interactions and mutations in the same tumor section by multiplex immunohistochemistry and NGS in immuno-oncology trials | Nathan Riccitelli; Jennifer M. Bordeaux, PhD; Nancy Valencia; Ju Young Kim, PhD; Sarah Johnson; Nathan Roscoe; James Santos; Justin Santos; Jacob Levy; Deepika Asnani; Tracie Cobb; Angela McIntosh; Xun Li, MD; Shabnam Tangri, PhD; Reinhold Pollner, PhD; Naveen Dakappagari, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 75 | Poster Presentation | Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer | Dante S. Bortone; Steven Vensko; Sarah Entwistle; Alexandria P. Cogdill, MEng; Anne Monette, PhD; Yana G. Najjar, MD; Randy F. Sweis, MD; Nicholas Tschernia, MD; Erik Wennerberg, PhD; Praveen K. Bommareddy, MS, PhD; Cara Haymaker, PhD; Uqba Khan, MD; Heather M. McGee, MD, PhD; Wungki Park, MD; Houssein A. Sater; Christine Spencer; Maria L. Ascierto, PhD; Valentin Barsan, MD; Vinita Popat, BA; Sara Valpione, MD, PhD; Danny Wells, BA, PhD; Vésteinn Thorsson, PhD; Roberta Zappasodi, Phd; Nils Rudqvist, PhD; Benjamin G. Vincent, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune contexture; Immune monitoring; RNA; Systems biology; Tumor microenvironment |
| 76 | Poster Presentation | Potential Mechanisms of Resistance Identified Through Analysis of Multiple Biomarkers in Immune Hot Non-Responders With Non-Small Cell Lung Cancer (NSCLC) Treated With Tislelizumab | Jayesh Desai, MBBS FRACP; Qing Zhou; Sanjeev Deva; Jun Zhao; Jie Wang; Wei Tan; Xiaopeng Ma; Yun Zhang; Zhirong Shen; Xikun Wu; Shiangjiin Leaw; Juan Zhang; Yi-Long Wu, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Angiogenesis; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; T cell lineages; Tumor microenvironment |
| 77 | Poster Presentation | Association Between Programmed Death-Ligand 1 (PD-L1) Expression and Gene Signatures of Response or Resistance to Tislelizumab Monotherapy in Hepatocellular Carcinoma (HCC) | Ming-Mo Hou; Kun-Ming Rau; Yoon-Koo Kang; Jong-Seok Lee; Hongming Pan; Ying Yuan; Cunjing Yu; Yun Zhang; Xiaopeng Ma; Xikun Wu; Xin Li; Katie Wood; Chia-Jui Yen, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment |
| 78 | Poster Presentation | T-Cell, MHC I, and Tumor Intrinsic Gene Signatures Predict Clinical Benefit and Resistance to Tislelizumab Monotherapy in Pretreated PD-L1+ Urothelial Carcinoma | Dingwei Ye; Aiping Zhou; Qing Zou; Hanzhong Li; Cheng Fu; Hailong Hu; Jian Huang; Wei Shen; Yun Zhang; Xiaopeng Ma; Pei Zhang; Ruiqi Huang; Xiusong Qiu; Lilin Zhang; Feng Bi; | Biomarkers, Immune Monitoring and Novel Technologies | Angiogenesis; Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical trial; Immune contexture; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 79 | Poster Presentation | Tumor-Immune Signatures Associated With Response or Resistance to Tislelizumab (Anti-PD-1) in Esophageal Squamous Cell Carcinoma (ESCC) | Jianming Xu; Nong Xu; Yuxian Bai; Chia-Chi Lin, MD, PhD; Michael Millward; Jingwen Shi; Yun Zhang; Xiaopeng Ma; Zhirong Shen; Ruiqi Huang; Wei Huang; Lin Shen, MD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment |
| 80 | Poster Presentation | Evaluation of the TruSight Oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab | Bo Wei, MS; John Kang; Miho Kibukawa, MS; Gladys Arreaza; Maureen Maguire; Lei Chen; Ping Qiu, PhD; Lixin Lang, PhD; Deepti Aurora-Garg, PhD; Razvan Cristescu, PhD; Diane Levitan, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors |
| 81 | Poster Presentation | Inclusion of PD-L1-expressing tumor cells in the Combined Positive Score algorithm yields superior identification of positive specimens around diagnostic cut-offs across multiple indications | Jay Milo, MAS; Christopher LaPlaca; Julia Hand; Stephanie Hund; Angeliki Apostolaki; Lindsay Guerrero; Kenneth Emancipator, MD; Jonathan Juco, MD; Bryce Portier; Siena Tabuena-Frolli; Karina Kulangara; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Antigen presenting cells; Bioinformatics; Biomarkers; Chemotherapy; Solid tumors; T cell |
| 82 | Poster Presentation | SQ3370 is a novel approach that decreases adverse drug exposure and achieves robust injected and non-injected anti-tumor responses | Sangeetha Srinivasan, PhD; Nathan A. Yee, PhD; Kui Wu, PhD; Amir Mahmoodi, MS; Michael Zakharian, MS; Maksim Royzen, PhD; Jose M. Mejia Oneto, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Chemotherapy; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 84 | Poster Presentation | Quantifying pharmacodynamic biomarker changes in immuno-oncology by mass spectrometry | Joseph M. Eckenrode, PhD; Omar F. Laterza, PhD; Michael E. Lassman, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Proteomics; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 85 | Poster Presentation | Spatial Heterogeneity of Tumor Associated Macrophages in the Tumor Immune Microenvironment in ccRCC | Nicholas H. Chakiryan, MD; Gregory Kimmel; Youngchul Kim, PhD; Jonathan Nguyen; Jad Chahoud; Philippe Spiess; Jasreman Dhillon, MD; Liang Wang; Carlos Moran-Segura; James J. Mule, PhD; Philipp Altrock; Brandon J. Manley; | Biomarkers, Immune Monitoring and Novel Technologies | Monocyte/Macrophage; Myeloid cells; Solid tumors |
| 86 | Poster Presentation | Co-detection of RNA and protein in FFPE tumor samples by combining RNAscope in situ hybridization and immunohistochemistry assays | Anushka Dikshit, PhD; Xiao-jun Ma, PhD; Emerald Doolittle, PhD; Lydia Hernandez, PhD; Jyoti Sheldon; Siobhan Kernag, PhD; Helly Xiao Yan Pimentel; Hailing Zong, PhD; Bingqing Zhang, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Cytokine; Gene expression; RNA; Tumor microenvironment |
| 87 | Poster Presentation | Transcription factor RUNX1 activates OPN to promote tumor progression via MAPK signaling in head and neck cancer | Kai Liu, Ph.D; Huiying Hu; Zhenkun Yu; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Carcinogenesis; Gene expression; Solid tumors; Tumor evasion |
| 88 | Poster Presentation | Development of a 3D organoid autologous TIL co-culture platform for high throughput immuno-oncology studies | Garima Kaushik, PhD; Bhavna Verma, PhD; Amy K. Wesa, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Checkpoint blockade; Cytokine; Immune suppression; Immune tolerance; NK/NK T cell; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
